Therapeutic HPV vaccines

HPV vaccines prophylactic, not therapeutic.

Chapter 7 Therapeutic Human Papillomavirus ( HPV ) Vaccines

Cervical cancer trends to occur in midlife. Most cases are found in women younger than 50. More than 15% of cases of cervical cancer are found in women over 65 but, these cancers rarely arrise in women who have regular tests for cervical cancer screening before they were 65. The most important etiological factor in cervical cancer and precursor lesions is persistent infection by HPV. Thus, an e...

Therapeutic Human Papillomavirus (HPV) Vaccines: A Novel Approach

Cervical cancer is the second largest cause of cancer-related death in women worldwide, and it occurs following persistent infection, sometimes for decades, with a specific subset of human papillomavirus (HPV) types; the approximately 13 oncogenic subtypes. Prophylactic vaccines against HPV infections hold promise for cost-effective reductions in the incidence of cervical cancer, but this may n...

HPV and Therapeutic Vaccines: Where are We in 2010?

The discovery of human papillomavirus (HPV) as a necessary etiological factor for cervical cancer has spurred the development of preventive and therapeutic HPV vaccines for the control of HPV-associated malignancies including cervical, vulvar, vaginal, and a subset of head and neck cancers. The commercial preventive HPV vaccines, Gardasil and Cervarix, use HPV virus-like particles to generate n...

Prophylactic HPV vaccines.

The HPV L1 VLP vaccines are immensely important developments in public health and the benefits that they promise are immense, offering the opportunity to prevent, in the long term, 80% of cervical cancers, 60% of vulval cancers and 80% of anal cancers in women. In the short to medium term they will prevent at least 90% of genital warts and have a major impact on the incidence of high grade CIN,...